Evidence map›Paper›PMID 31540867›Full record

Trial reportThe lancet. Diabetes & endocrinology2019

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.

Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen, Rory J McCrimmon

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03136484. Cited by 138 papers, 23 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 23 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03136484 phase3completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Ran2017Enrolled788Registered outcomes61Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsCanagliflozin, Placebo (canagliflozin), Placebo (semaglutide), semaglutide
PMID 31897524other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 23 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ildiko LingvayDepartment of Internal Medicine/Endocrinology, Department of Clinical Sciences, UT Southwestern Medical Center, University of Texas, Dallas, TX, USA. Electronic address: ildiko.lingvay@UTSouthwestern.edu.
Andrei-Mircea CatarigNovo Nordisk, Søborg, Denmark.
Juan P FriasNational Research Institute, Los Angeles, CA, USA.
Harish KumarCentre for Endocrinology and Diabetes, Amrita Hospital, Kochi, India.
Nanna L LausvigNovo Nordisk, Søborg, Denmark.
Carel W le RouxDiabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
Desirée ThielkeNovo Nordisk, Søborg, Denmark.
Adie ViljoenBorthwick Diabetes Research Centre, Stevenage, UK.
Rory J McCrimmonSchool of Medicine, University of Dundee, Dundee, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExisting guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the efficacy and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozin (an SGLT2 inhibitor) in patients with type 2 diabetes.

methodsThis was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries. Eligible patients were at least 18 years old and had uncontrolled type 2 diabetes (HbA

findingsBetween March 15, 2017, and Nov 16, 2018, 788 patients were randomly assigned to semaglutide 1·0 mg (394 patients) or canagliflozin 300 mg (394 patients). 739 patients completed the trial (367 in the semaglutide group and 372 in the canagliflozin group). From overall baseline mean, patients receiving semaglutide had significantly greater reductions in HbA

interpretationOnce-weekly semaglutide 1·0 mg was superior to daily canagliflozin 300 mg in reducing HbA

fundingNovo Nordisk.

Indexed as

AdultAgedBody WeightCanagliflozinDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsMaleMetforminMiddle AgedSemaglutideCanagliflozinGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsMetforminSemaglutideSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID31540867

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.